Andes Hantavirus Testing: A Practical Guide for Travelers, Clinicians, and Labs (2026)

If you were recently on a cruise or traveled in parts of South America where Andes hantavirus circulates—and you’re wondering whether to get tested—the short answer is: consider testing if you had close contact with a confirmed case, developed flu-like symptoms within a few weeks of return, or were notified of a potential exposure on your trip. A new university lab-developed test in the US is being stood up to detect infection earlier in the course of illness, potentially before the most dangerous phase. Contact your clinician or state health department to request testing; they can coordinate with reference laboratories now offering Andes hantavirus assays.

For clinicians and labs: plan for a nucleic-acid–first approach in the first week of illness (or for asymptomatic high-risk contacts), followed by serology if symptoms started more than a week ago. Because Andes hantavirus can, in rare cases, spread person-to-person, early confirmation changes infection-control decisions and triggers contact monitoring. Below you’ll find clear criteria for who to test, how the new early-detection option fits with existing assays, and step-by-step access pathways in the US.

What Changed This Week—and Why It Matters

• A US university public-health laboratory has announced an early-detection test for Andes hantavirus (ANDV) and is preparing to screen returning travelers linked to a cruise outbreak. While details of the platform and performance are emerging, the goal is to detect infection earlier than traditional diagnostics typically do.
• Early confirmation matters for three reasons:
  • Clinical care: Patients deteriorate rapidly during the cardiopulmonary phase; early identification enables monitoring, timely transfer, and supportive care planning (including ECMO referral when available).
  • Infection control: Unlike most hantaviruses, ANDV has documented person-to-person transmission with close contact. A lab-confirmed diagnosis guides isolation precautions and contact tracing.
  • Public health: Faster case finding curbs secondary spread in households and congregate settings.

Quick Background: What Is Andes Hantavirus?

• Geography: Identified primarily in parts of Argentina and Chile, ANDV causes hantavirus pulmonary syndrome (HPS), a severe illness with a high case-fatality rate.
• Transmission: Most hantavirus infections stem from contact with infected rodent excreta. ANDV is unusual because close person-to-person transmission has been documented, particularly among intimate partners and household contacts during the early phase of illness.
• Timeline: Incubation is typically 1–2 weeks but can extend longer. Early symptoms mimic a viral flu: fever, myalgias, headache, GI upset. The critical cardiopulmonary phase can follow abruptly.

Who Should Consider Testing Right Now

Use these tiers to decide when to test or escalate to public health.

• Tier 1 (Test now; consider home isolation while awaiting results):

  • You were notified that you are a close contact of a confirmed Andes hantavirus case, regardless of symptoms.
  • You have fever or flu-like symptoms within 8–42 days after travel to known ANDV regions (notably parts of southern South America) or a cruise with a confirmed outbreak.
  • You had unprotected, close, prolonged contact (household, intimate partner, shared small indoor space) with a symptomatic traveler from an affected setting.

• Tier 2 (Consult your clinician or public health; testing likely appropriate):

  • You had environmental exposure to rodent-infested settings in endemic areas (cabins, barns, rural lodges) and developed compatible symptoms.
  • You are a healthcare worker or caregiver with unprotected close contact to respiratory secretions or body fluids of a suspected case.

• Tier 3 (Monitor; test if symptoms develop or if directed by public health):

  • You were on the same large conveyance (e.g., cruise ship) without known close contact but received an exposure notice.

If you develop shortness of breath, chest tightness, dizziness, or sudden worsening, seek emergency care immediately and inform staff of possible Andes hantavirus exposure.

The Testing Landscape: Options, Windows, and Trade-offs

There is no single “best” test for every situation. Timing relative to symptom onset is the most important factor.

• Nucleic acid amplification tests (NAATs), including RT-PCR

  • What they detect: Viral RNA in blood or, in some protocols, respiratory or saliva samples.
  • Window: Highest yield during the early (prodromal) phase and early cardiopulmonary phase. Some emerging assays aim to detect RNA even before symptoms.
  • Pros: Early positivity; highly specific.
  • Cons: Requires specialized labs and biosafety practices; false negatives can occur if sampling is late or viral loads are low.

• Serology (IgM/IgG antibody tests)

  • What they detect: The body’s immune response to infection.
  • Window: IgM generally appears around or after the first week of symptoms; IgG follows.
  • Pros: Useful when the patient presents later; can support diagnosis when RNA is no longer detectable.
  • Cons: Not helpful very early; potential cross-reactivity across hantaviruses in some assays.

• Antigen/other rapid methods

  • Limited availability for ANDV; most current front-line diagnostics are NAAT or serology in reference labs.

• Metagenomic/viral sequencing

  • Occasionally used by research or public health labs for confirmation and epidemiology; not a first-line clinical test.

Bottom line: If it’s early or you’re asymptomatic but a high-risk contact, prioritize NAAT. If it’s day 7 or later after symptom onset, add serology.

What We Know About the New Early-Detection Test

A US academic public-health lab has readied a test designed to detect Andes hantavirus earlier in the disease course, and it is being deployed to evaluate travelers returning from a cruise-linked outbreak.

• Likely positioning: A nucleic-acid–based assay intended for use in a certified public-health or academic lab setting.
• Intended benefit: Compress the time to confirmation by detecting infection ahead of severe cardiopulmonary symptoms.
• Access: Expect clinician- or public-health–mediated access, not direct-to-consumer ordering.
• Regulatory status: Many such assays begin as CLIA laboratory-developed tests (LDTs). Ask the ordering lab about current authorization and reporting pathways.
• Practical questions to ask when ordering:
  • What sample type and volume are needed (whole blood, serum, plasma, swab, saliva)?
  • What is the expected turnaround time from receipt?
  • Should repeat testing be done if the first test is negative but suspicion remains high?
  • Will the lab reflex to serology at day 7+ of symptoms?

Because platform details and performance metrics are still being characterized, negative results early after exposure should be interpreted with clinical judgment and, if warranted, repeated.

How to Access Testing in the United States

1. Start with your clinician.

   • Explain your exposure details (dates, locations, type of contact) and symptoms.
   • Ask them to consult your state or local health department if Andes hantavirus is suspected.

2. Engage public health early.

   • State health departments can coordinate testing at reference laboratories and determine if your case meets criteria for priority processing.
   • They can advise on isolation, contact notification, and return-to-work guidance.

3. Reference labs and academic centers.

   • Certain university or public-health laboratories now perform ANDV assays, including the new early-detection test.
   • Your clinician or health department will arrange shipping and requisitions; these are not retail tests.

4. Insurance and cost.

   • Public-health testing linked to outbreak response may be covered or subsidized. Private insurance coverage varies; obtain an estimate when possible.

5. Results and next steps.

   • If positive: Your care team and public health will advise monitoring, potential hospitalization thresholds, and contact management.
   • If negative but suspicion is high: Plan for repeat NAAT in 24–48 hours and/or serology at day 7+ after symptom onset.

A 10-Day Action Plan for Cruise Returnees Notified of Exposure

• Day 0: Document exposure date; line up a telehealth or clinic appointment.
• Days 1–10: Self-monitor twice daily for fever and symptoms (aches, GI upset, cough, chest symptoms).
• Reduce close, prolonged indoor contact with high-risk household members; consider masking in shared spaces if feasible.
• If you develop symptoms: Isolate from others at home and contact your clinician the same day about testing.
• If you are a high-risk contact (intimate partner of a confirmed case): Request early NAAT now and a repeat test if the first is negative.

Clinical Algorithm for Suspected Andes Hantavirus (For Healthcare Providers)

• Pretest probability

  • Travel within 8–42 days to endemic regions OR exposure to a confirmed case.
  • Compatible symptoms: fever, myalgias, GI symptoms; watch for hypotension, thrombocytopenia, rising hematocrit.

• Immediate steps

  • Institution-level isolation per droplet/standard precautions; add eye protection for close-contact care.
  • Notify infection prevention and local/state health department.

• Testing sequence

  • ≤7 days from symptom onset or asymptomatic high-risk contact: Order NAAT on appropriate sample. If negative but suspicion remains, repeat in 24–48 hours.

  • 7 days from onset: Add hantavirus IgM/IgG serology; maintain NAAT if within diagnostic window.

• Differential to consider

  • Influenza, COVID-19, atypical bacterial pneumonia, leptospirosis, rickettsioses, dengue, hantaviruses other than ANDV.

• Disposition

  • Arrange close follow-up; low threshold for hospital observation if vitals or labs are concerning. Identify ECMO-capable centers early for rapid transfer if clinical trajectory worsens.

Laboratory and Biosafety Notes (For Lab Directors)

• Risk assessment: Processing should follow risk-based biosafety procedures; hantaviruses warrant heightened precautions, particularly for manipulations that can generate aerosols.
• Packaging and shipping: Coordinate with the reference lab for specimen type, temperature, and UN classification; use triple packaging and chain-of-custody documentation.
• Communication: Establish 24/7 points of contact with the receiving lab for expedited reporting during outbreak response.

What Early Diagnosis Changes in Practice

• Patient outcomes: While there’s no widely approved antiviral specifically for ANDV, early diagnosis enables anticipatory supportive care, fluid management, vasopressor readiness, and ECMO referral where available—all associated with improved survival in severe cardiopulmonary syndromes.
• Public health: Confirmed cases trigger active monitoring of close contacts and can prevent secondary transmission in households and healthcare settings.
• Resource allocation: Identifying who needs escalation avoids both overuse and dangerous delays.

Pros and Cons of Testing Now

• Pros

  • Earlier warning for rapid deterioration windows.
  • Clear guidance for isolation and contact management.
  • Contributes to outbreak control and situational awareness.

• Cons

  • Early tests may yield false negatives; repeat testing can be needed.
  • Access may be limited to public-health/academic labs; turnaround can vary.
  • Anxiety and logistical burdens if capacity is strained.

Key Takeaways

• If you had close contact with a confirmed Andes hantavirus case or developed compatible symptoms after travel to affected areas or a cruise outbreak, seek testing promptly.
• Early NAAT is the best first step; add serology after a week of symptoms. Negative early results may need repeating.
• A new early-detection lab test is being deployed in the US to catch infections sooner; access it through your clinician and public health.
• Early confirmation drives better clinical monitoring and reduces the chance of secondary spread.

FAQ

• Can Andes hantavirus spread person-to-person?

  • Yes, unlike most hantaviruses, ANDV has documented close-contact transmission, especially in households. It’s not known to spread like common respiratory viruses in casual community settings.

• What is the incubation period?

  • Typically 1–2 weeks, with reported ranges that can be longer. Maintain vigilance for up to six weeks after high-risk exposure.

• Is there an at-home rapid test?

  • No. Current diagnostics are performed in certified laboratories.

• Will my insurance cover testing?

  • Coverage varies. Public-health–coordinated testing during outbreaks may be subsidized. Ask your clinician or health department.

• If my early test is negative, am I in the clear?

  • Not necessarily. If you tested very soon after exposure or symptom onset, repeat testing may be recommended, and serology may be added later.

• Is there a vaccine or treatment?

  • No widely available vaccine exists. Care is supportive, with aggressive management of the cardiopulmonary phase. Experimental or investigational therapies may be considered in protocols, but availability is limited.

Source & original reading: https://www.wired.com/story/race-to-develop-andes-hantavirus-test/